Edesa Biotech, Inc.

228 articles with Edesa Biotech, Inc.

• Edesa Biotech to Present at Upcoming H.C. Wainwright 24th Annual Global Investor Conference

  9/8/2022

  Edesa Biotech, Inc. announced that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.

• Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

  9/7/2022

  Edesa Biotech, Inc. announced that patient recruitment has been completed for a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis.

• Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

  8/12/2022

  Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three and nine months ended June 30, 2022 and provided an update on its business.

• Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

  8/3/2022

  Edesa Biotech, Inc. announced today that its executive management will participate in the upcoming BTIG Biotechnology Conference being held in New York, NY on August 8-9, 2022.

• Edesa Biotech to Present at ARDS Drug Development Summit

  7/11/2022

  Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development Summit being held July 13-15, 2022 in Boston, Mass.

• 

  Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More

  5/30/2022

  A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

• Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

  5/24/2022

  Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Phase 2/3 study of the company's critical care drug candidate, designated EB05.

• Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

  5/19/2022

  Edesa Biotech, Inc. announced that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

• Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

  5/13/2022

  Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.

• Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

  4/28/2022

  Edesa Biotech, Inc. announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis has been enrolling ahead of schedule.

• Edesa Biotech Appoints Strategy Expert to Board of Directors

  3/29/2022

  Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the appointment of Jennifer M. Chao to the company's Board of Directors.

• Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

  3/24/2022

  Edesa Biotech, Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor of 2,739,727 of the Company's common shares at a purchase price of $3.65 per common share.

• Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  3/22/2022

  Edesa Biotech, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,739,727 of the Company's common shares.

• Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

  2/17/2022

  Edesa Biotech, Inc. today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.

• Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

  2/14/2022

  Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, reported financial results for the three months ended December 31, 2021 and provided an update on its business.

• Edesa Biotech to Join Ontario Bioscience Panel Discussion

  1/26/2022

  Edesa Biotech, Inc. announced that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.

• Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

  1/13/2022

  Edesa Biotech, Inc. today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study.

• Edesa Biotech Reports Fiscal Year 2021 Results

  12/28/2021

  Edesa Biotech, Inc. today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business.

• Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

  12/1/2021

  Edesa Biotech, Inc. today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis.

• Edesa Biotech Extends COVID-19 Clinical Study to Poland

  11/4/2021

  Edesa Biotech, Inc. today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody candidate, designated EB05